The clinical and cost-effectiveness of supplemental parenteral nutrition in oncology
Open Access
- 1 January 2020
- journal article
- research article
- Published by Elsevier BV in ESMO Open
- Vol. 5 (3), e000709
- https://doi.org/10.1136/esmoopen-2020-000709
Abstract
Background Clinical guidelines recommend that parenteral nutrition (PN) is added to enteral nutrition (EN; supplemental parenteral nutrition (SPN)) in order to meet energy and protein needs in patients with cancer when EN alone is insufficient. However, although cancer-related malnutrition is common, there is poor awareness of the value of nutritional care, resulting in SPN being chronically underused. Methods We performed a targeted literature review and exploratory cost-utility analysis to gather evidence on the clinical effectiveness of SPN, and to estimate the potential cost-effectiveness of SPN versus EN alone in an example cancer setting. Results The literature review identified studies linking SPN with malnutrition markers, and studies linking malnutrition markers with clinical outcomes. SPN was linked to improvements in body mass index (BMI), fat-free mass, phase angle (PhA) and prealbumin. Of these markers, BMI and PhA were strong predictors of survival. By combining published data, we generated indirect estimates of the overall survival HR associated with SPN; these ranged from 0.80 to 0.99 (mode 0.87). In patients with Stage IV inoperable pancreatic cancer, the incremental cost-effectiveness ratio versus EN alone was estimated to be £41 350 or £91 501 depending on whether nursing and home delivery costs for EN and SPN were combined or provided separately. Conclusion Despite a lack of direct evidence, the results of the literature review demonstrate that SPN may provide important clinical and quality of life benefits to patients with cancer. The potential for any improvement in outcomes in the modelled patient population is very limited, so cost-effectiveness may be greater in patients with less severe disease and other types of cancer.This publication has 55 references indexed in Scilit:
- Pretreatment malnutrition and quality of life - association with prolonged length of hospital stay among patients with gynecological cancer: a cohort studyBMC Cancer, 2010
- Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II studyBMC Cancer, 2010
- Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer CentresBritish Journal of Cancer, 2010
- Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinomaAnnals of Oncology, 2010
- Bioelectrical impedance phase angle in clinical practice: implications for prognosis in stage IIIB and IV non-small cell lung cancerBMC Cancer, 2009
- Bioelectrical impedance phase angle as a prognostic indicator in breast cancerBMC Cancer, 2008
- Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?European Journal of Cancer, 1998
- Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patientsNutrition and Cancer, 1998
- Prognostic effect of weight loss prior tochemotherapy in cancer patientsThe American Journal of Medicine, 1980
- Causes of death in patients with cancerEuropean Journal of Cancer (1965), 1972